Independent DSMB Recommends MediWound's EscharEx® Phase III VALUE Study Continue Without Modification

Stock Information for MediWound Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About MediWound Ltd.

MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference
MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update
MediWound to Report Second Quarter 2026 Financial Results
MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
MediWound to Report First Quarter 2026 Financial Results
Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.